Pfizer growth over the years

·Pharma & HealthChart ›
ProfitabilityGrowthCreditLiquidityWorking capitalDividend yieldDuPontCAGR
Compounded a year1 yr3 yr
Revenue+10.5%+1.3%
EBITDA+22.2%+3.8%
Net Income−5.9%+5.0%
Total Assets+0.2%+7.1%
Total Equity−0.3%+9.4%
Free Cash Flow+49.2%—
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

PFIZER₹3,734.40

Pfizer Ltd.

· Pharma & Health
₹ CrorePeersGLAXOABBOTINDIAPOLYMEDONESOURCERAINBOWKIMSJUBLPHARMAVIJAYA
Annuals · FY-end closes
Compounded Growth
Annuals · CAGR %
1Y
CAGR
3Y
CAGR
Revenue+10.5+1.3
EBITDA+22.2+3.8
Net Income-5.9+5.0
Total Assets+0.2+7.1
Total Equity-0.3+9.4
Free Cash Flow+49.2—
CAGR from filed annuals — needs positive start & end values.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 85%.